Project Grant K99CA300924
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$117K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to support the development of a novel light-activatable nanoplatform for the targeted co-delivery of photodynamic therapy (PDT) and chemotherapy to treat peritoneal metastasis. The key objectives are to: 1) compare the pharmacokinetics and biodistribution of the nanoplatform following intravenous or intraperitoneal administration,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,373,308 to the University of Pittsburgh to conduct research on the role of acetylcarnitine metabolism in ovarian cancer chemoresistance. The project aims to: 1) quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, and 2) investigate whether interventions that...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $137,322 to Trustees of Boston University to develop disulfated polyamidosaccharide (DISULPAS) nanoparticles for the targeted delivery of chemotherapeutics to metastasizing cancer cells. The goal is to create a synthetic fucoidan mimetic that can more consistently bind to the P-selectin protein, which is upregulated on many tumor cells and plays a key role in metastasis. The project will...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore to conduct research on the mechanisms by which chemotherapy used to treat epithelial ovarian cancer (including the high-grade serous ovarian cancer subtype) can paradoxically promote metastasis. The goal is to determine how chemotherapy activates tumor-associated membrane-anchored serine proteases that enable cancer cell...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...